Amadix — Series A · €1.5M

Amadix closed a €1.5M capital increase from private investors and family offices, after opening a search for up to €2.5M in June 2018 with support from the Junta de Castilla y León and the Alentia investor network; the money was to strengthen the commercial strategy for the Colofast blood test. Press at the time noted three earlier capital increases totalling over €2M since 2010, plus a separate €2.8M Horizon 2020 grant awarded in 2017, which is not counted as a round here.